Eli Lilly announced on August 31 that it has entered into a definitive agreement to acquire Merida Biosciences, a U.S. biotech developing therapies for serious autoimmune and allergic diseases, for up to $2.875 billion in cash. The total includes an upfront payment and contingent milestone payments, with closing expected in Q4 2026. Merida is developing […]
- info-gsls@greenstafflifesciences.com
- Mon - Fri: 9.00 - 18.00 (JST)
- Accessibility